Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health Inc. ownership filing by T. Rowe Price Associates, Inc. reports beneficial ownership of 7,035,771 shares of Common Stock, representing 5.4% of the class as of 03/31/2026. The filing lists sole voting power for 6,842,514 shares and sole dispositive power for 7,035,771 shares. The filing is signed by Ellen York, Vice President, on 05/15/2026.
Guardant Health, Inc. Co-Chief Executive Officer and director AmirAli Talasaz reported an open-market sale of 50,000 shares of Common Stock on May 12, 2026. The shares were sold at a weighted average price of $100.32 per share in multiple trades.
After this transaction, 2,096,504 shares of Guardant Health Common Stock are reported as indirectly owned, held by the Talasaz and Eskandari 2017 Family Trust.
GH filed a Rule 144 notice identifying multiple classes of Common Stock and equity awards subject to sale or disposition. The excerpt lists specific lots, dates and quantities including open market purchases, restricted stock units, stock options and founder shares with entries such as 100,000 founder shares (09/22/2018) and smaller award lots dated between 2020 and 2024.
Guardant Health, Inc. reported strong top-line growth but continued losses for the quarter ended March 31, 2026. Revenue rose to $301.7 million from $203.5 million a year earlier, driven by oncology, biopharma and data, and a sharp increase in screening revenue.
The company posted a net loss of $112.1 million, compared with a $95.2 million loss, with higher sales and marketing and ongoing R&D spending. Cash, cash equivalents and restricted cash totaled $1.10 billion, while convertible senior notes had a net carrying amount of $1.50 billion, leaving Guardant in a stockholders’ deficit of $181.1 million.
Guardant continues to expand its precision oncology and colorectal screening portfolio, including FDA‑approved Shield and Guardant360 tests, while managing significant legal matters. A prior $83.4 million patent verdict against the company remains under challenge, and Guardant has a $287.0 million false‑advertising judgment in its favor in separate litigation.
Guardant Health reported strong first-quarter 2026 growth and raised its full-year 2026 revenue guidance to $1.30–$1.32 billion, implying 32%–34% growth over 2025. Revenue for the quarter rose 48% to $301.7 million, led by oncology revenue of $205.0 million, screening revenue of $41.6 million, and biopharma and data revenue of $53.0 million.
Non-GAAP gross margin improved to 66%, while non-GAAP operating expenses rose to $268.1 million as the company invested in commercial expansion, particularly for its Shield screening business. Guardant remained loss-making, with GAAP net loss of $112.1 million and non-GAAP net loss of $58.7 million, and free cash flow of negative $71.2 million.
The company now expects screening revenue of $186–$198 million in 2026, driven by 230,000–245,000 Shield tests, and continues to target full-year non-GAAP gross margin of 64%–65% and free cash flow burn of $185–$195 million, better than 2025. Cash, cash equivalents, restricted cash and marketable securities totaled about $1.2 billion as of March 31, 2026.
Guardant Health, Inc. director Steve E. Krognes exercised restricted stock units into common stock in a routine compensation-related transaction. On April 30, 2026, 154 common shares were acquired upon RSU vesting, bringing his direct common stock holdings to 19,362 shares.
The RSUs originated from an award granted on August 9, 2022, with 25% vesting on June 30, 2023 and the remaining 75% vesting in substantially equal monthly installments over three years. After this vesting event, he holds 309 restricted stock units directly.
Vanguard Capital Management reported holding 6,589,394 shares of Guardant Health common stock, representing 5.02% of the class as of 03/31/2026. The filing shows sole dispositive power over 6,589,394 shares and sole voting power over 965,214 shares. The Schedule 13G form is signed by Ashley Grim as Head of Global Fund Administration on 04/30/2026.
Guardant Health is asking stockholders to vote at its virtual 2026 annual meeting on June 17, 2026, where they will elect two Class II directors, ratify Deloitte as auditor, and hold advisory votes on executive pay and the frequency of future pay votes.
The proxy highlights a strong 2025, with 363,000 clinical tests and $982 million in revenue, representing 33% year-over-year growth. Screening advanced with about 87,000 Shield tests, generating roughly $80 million and securing a $1,495 Medicare rate and guideline inclusion. The Board reports 9 of 11 directors as independent, increasing its focus on governance, ESG reporting and pay-for-performance programs that tie bonuses and performance share units to revenue growth, adjusted EBITDA and long-term shareholder returns.
Guardant Health, Inc. disclosed that its Chief Medical Officer, Craig Eagle, M.D., has resigned. His resignation is scheduled to take effect on May 8, 2026. The company reported this leadership change in a current report signed by its Chief Legal Officer and Corporate Secretary, John G. Saia.